Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.Matthew S. Davids, Andrew W. Roberts, Martin Dunbar et al.|Journal of Clinical Oncology|2014Cited by 91
Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)Matthew S. Davids, Andrew W. Roberts, John M. Pagel et al.|Blood|2013Cited by 69
ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.John F. Seymour, Andrew W. Roberts, Matthew S. Davids et al.|Journal of Clinical Oncology|2014Cited by 56
The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) PatientsMatthew S. Davids, Andrew W. Roberts, John F. Seymour et al.|Blood|2013Cited by 53
Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)Andrew W. Roberts, John F. Seymour, Shuo Ma et al.|Blood|2014Cited by 44